Compare The Coca-Cola Co K (KO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Regeneron Pharmaceuticals Inc — how do they compare? The Coca-Cola Co K trades at $81.9 (market cap $353.32B), while Regeneron Pharmaceuticals Inc trades at $676.29 (market cap $70.47B). The key difference: The Coca-Cola Co K is far larger — about 5× Regeneron Pharmaceuticals Inc's market cap, and The Coca-Cola Co K pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| KO | REGN | |
|---|---|---|
Market Cap | $353.32B | $70.47B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $812.27 |
52-Week Low | $65.67 | $545.46 |
Enterprise Value | $383.39B | $64.42B |
Dividend Yield | 2.58% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.74, up 0.22% today, with a bearish technical signal but strong fundamentals including 27.8% net margin and consistent earnings beats. The stock shows robust profitability with ROE at 45.8% and positive cash flow trends, supported by a $0.53 quarterly dividend. Recent news highlights institutional buying and stable demand ahead of Q2 2026 earnings.
Outlook remains positive with a $90.67 consensus price target implying 11% upside, though risks include regional demand divergence and high debt. Analyst sentiment is bullish (60% Buy), but technical resistance near $83 may limit near-term gains. Long-term investors may find value in KO's dividend stability and brand strength.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
